Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.57 |
| ▸ | HSPD1 | P10809 | 4/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 4/20 | 0.56 |
| ▸ | HSPE1 | P61604 | 4/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | SLC25A1 | P53007 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.49 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228187 | 0.89 | VCAM1 (0.64) | MAPTVCAM1DNMT1DNMT3AHSPD1 | |
| SCHEMBL5225915 | 0.86 | VCAM1 (0.64) | MAPTVCAM1DNMT1DNMT3AHSPD1 | |
| SCHEMBL3619380 | 0.86 | SLC25A1 (0.67) | MAPTVCAM1DNMT1DNMT3AHSPD1 | |
| SCHEMBL5225868 | 0.83 | VCAM1 (0.64) | VCAM1DNMT1DNMT3AHSPD1PTPN2 | |
| SCHEMBL5227253 | 0.83 | VCAM1 (0.57) | MAPTNPSR1VCAM1DNMT1DNMT3A | |
| SCHEMBL6677229 | 0.83 | VCAM1 (0.60) | MAPTVCAM1DNMT1DNMT3AHSPD1 | |
| SCHEMBL6679999 | 0.83 | VCAM1 (0.60) | MAPTVCAM1DNMT1DNMT3AHSPD1 | |
| SCHEMBL9722998 | 0.82 | VCAM1 (0.56) | VCAM1DNMT1DNMT3AHSPD1PTPN2 | |
| SCHEMBL1250772 | 0.81 | VCAM1 (0.62) | MAPTNPSR1VCAM1DNMT1DNMT3A | |
| SCHEMBL3615295 | 0.80 | VCAM1 (0.59) | MAPTNPSR1VCAM1DNMT1DNMT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107372504-B | Application of sulfonamide compound in enhancing plant stress resistance and medicament containing same | 华中师范大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885NPSR1 3949/4885VCAM1 1503/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885NPSR1 3949/4885VCAM1 1503/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAPT 1347/4885NPSR1 3949/4885VCAM1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.